secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001171843-21-007561
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Q3 net loss $33.1M ($0.78 loss per share); clinical programs advance
---------------------------------------------------------------------------

- Net loss $33.1M, EPS $(0.78) vs net loss $33.3M, EPS $(11.00) in Q3 2020.
- R&D expenses $28.1M (up from $17.3M) on continued development of three CHB candidates and NASH drug.
- Cash, cash equivalents and investments $242.7M as of Sep 30, 2021, down slightly from $243.5M.
- Dosing of ASO candidate ALG-020572 in healthy volunteers started; STOPS cohorts (120, 200 mg) fully enrolled.
- CTA filed for NASH candidate ALG-055009 (THR-β agonist); dosing in healthy volunteers expected Q4 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184321007561/0001171843-21-007561-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184321007561/f8k_110421.htm
  HTML page:      https://secwatch.observer/filing/0001171843-21-007561

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer